Soliris vs. Ultomiris for aHUS

Soliris vs. Ultomiris for aHUS
5
(1)

Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) are medications developed by Alexion to treat atypical hemolytic uremic syndrome (aHUS).

How are these medications similar?

Both Soliris and Ultomiris contain humanized antibodies, or antibodies that work with the human immune system. These medications block the complement system, a part of the immune system that amplifies the immune response. In aHUS, the complement system is overactivate, causing the symptoms of this disease.

Doctors administer both medications by intravenous infusion, a process of delivering the medication directly into the bloodstream, over a period averaging for adults about 35 minutes (for Soliris) to a few hours (for Ultomiris).

For each treatment, a loading dosage is infused until patients can move to more infrequent, maintenance dosages. This transition depends on how a particular patient responds to treatment.

Both Soliris and Ultomiris can lower the body’s ability to respond to infections. In particular, patients may be more susceptible to meningococcal disease. For this reason, patients of either medication must get a meningococcal vaccine before beginning treatment.

How do Soliris and Ultomiris differ?

The two medications have different formulations and may interact differently with a patient’s immune system.

Doctors give Ultomiris at a higher dose than Soliris, which is why an infusion for Ultomiris takes longer. However, patients on Ultomiris may be able to have their treatments further apart (once every four to eight weeks for maintenance) than those using Soliris, who typically undergo a maintenance treatment every two weeks.

Where can I find out more?

In order for you to be treated with either Soliris or Ultomiris, your doctor must enroll you in a patient program, as well as inform you on the precautions necessary to take while you are using either medication.

If you would like more information, please see our pages: FAQs about Soliris or FAQs about Ultomiris.

 

Last updated: Aug. 3, 2020

***

aHUS News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Total Posts: 0
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×
Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Latest Posts
  • Soliris and Ultomiris
  • soliris FAQs
  • soliris FAQs
  • planning for future

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?